Severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 are three kinds of coronaviruses that are exceptionally pathogenic to humans via zoonotic infections. The outbreaks of SARS-CoV and MERS-CoV, and SARS-CoV-2, to some extent, posed a severe threat to human health, daily activities as well as the economic status of many countries. When faced with these emerging viruses and no accessible vaccines and drugs, convalescent plasma (CP) is required as passive immunotherapy, since CP has the potential to neutralize and eliminate the virus from blood circulation. The sources of CP are individuals who have recovered from the viruses. Currently, CP is administered as emergency use and investigational treatment. Some studies have shown that CP is effective to treat infected individuals with viral pandemics such as influenza A, Ebola virus, SARS-CoV, and MERS-CoV. Moreover, following the deadly outbreak of SARS-CoV-2 in 2019, plenty of non-randomized clinical studies have been done on the effectiveness of CP for the treatment of Coronavirus Disease 2019 (COVID-19), and most of these studies have indicated that CP therapy is promising and saved many critically-ill patients. Therefore, CP is a helpful immune therapeutic agent for the immediate response of such pandemics because of its clinical efficacy, immediate availability, cost-effectiveness, ease of production, delivery, and storage. This review aims to summarize the effectiveness of CP in the treatment of these three coronaviruses, i.e. SARS-CoV, MERS-CoV, and SARS-CoV-2.